LC-MSn and HR-MS characterization of secondary metabolites from Hypericum japonicum Thunb. ex Murray from Nepalese Himalayan region and assessment of cytotoxic effect and inhibition of NF-κB and AP-1 transcription factors in vitro
Language English Country England, Great Britain Media print-electronic
Document type Journal Article
PubMed
31288189
DOI
10.1016/j.jpba.2019.06.042
PII: S0731-7085(19)31168-9
Knihovny.cz E-resources
- Keywords
- Anti-NF-κB, Cytotoxicity, Hypericaceae, Hypericum japonicum, Secondary metabolites, anti-AP-1,
- MeSH
- Anti-Inflammatory Agents pharmacology MeSH
- Biological Assay MeSH
- Cell Line MeSH
- Chromatography, Liquid MeSH
- Flavonoids pharmacology MeSH
- Phloroglucinol pharmacology MeSH
- Mass Spectrometry MeSH
- Hydroxybenzoates pharmacology MeSH
- Inhibitory Concentration 50 MeSH
- Humans MeSH
- NF-kappa B p50 Subunit antagonists & inhibitors MeSH
- Antineoplastic Agents pharmacology MeSH
- Plant Extracts pharmacology MeSH
- THP-1 Cells MeSH
- Transcription Factor AP-1 antagonists & inhibitors MeSH
- Hypericum chemistry MeSH
- Cell Survival MeSH
- Xanthones pharmacology MeSH
- Inflammation MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Nepal MeSH
- Names of Substances
- Anti-Inflammatory Agents MeSH
- Flavonoids MeSH
- Phloroglucinol MeSH
- Hydroxybenzoates MeSH
- NF-kappa B p50 Subunit MeSH
- NFKB1 protein, human MeSH Browser
- phenolic acid MeSH Browser
- Antineoplastic Agents MeSH
- Plant Extracts MeSH
- Transcription Factor AP-1 MeSH
- Xanthones MeSH
Hypericum japonicum Thunb. ex Murray is traditionally used in Nepal to treat several diseases, among whom inflammation and acute pain. Although several secondary metabolites from the same Hypericum species have been already characterized and considered for their pharmacological use, an exhaustive phytochemical characterization of H. japonicum from Nepal is lacking, as well as the assessment of its potential pharmacological properties. Hence, the aims of this study were the characterization of a methanolic extract of H. japonicum (HJME) collected from the Northern region of Nepal by LC-MSn and UPLC-QTOF. The assessment of in vitro inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1) transcription factors and HJME's cytotoxic effect on human cell lines was performed to evaluate the potential use of this herb as a source of anti-inflammatory and cytotoxic lead compounds. Fifty-seven phytoconstituents were identified, being mainly flavonoids, phloroglucinols, phenolic acids and xanthones. Although compounds characteristic of H. japonicum were detected (quercetin, quercetin-7-O-α-l-rhamnoside, quercitrin and hyperoside), several others are here reported for the first time in this species. The results from bioassays indicated that HJME could significantly reduce the viability of human THP-1 cells (IC50 = 5.4 ± 1.1 μg mL-1), showing the promising potential of HJME as anti-tumor agent. Furthermore, HJME significantly decreased the activation of both NF-κB and AP-1 at the concentration of 2 μg mL-1. Overall, these data suggest that H. japonicum from Nepal could be used as a source of potential natural anti-inflammatory and anti-tumor lead compounds.
References provided by Crossref.org